Zubair Hussain

Zubair Hussain

Auto-generated profile, based on publicly available information

Zubair Hussain

Department of Clinical Laboratory, the Third Xiangya Hospital of Central South University, Changsha 410013, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Experimental Cell Research
Verified
Journal Article
Closed access
HLHongcai Liu
Hongcai Liu
ZHZubair Hussain
Zubair Hussain
QXQingqing Xie
Qingqing Xie
XYXueying Yan
Xueying Yan
CZChenxing Zeng
Chenxing Zeng
SCShan Cao
Shan Cao

24 September 2022 in Pathogens and Disease
Verified
Journal Article
Closed access
PDF file
ZHZubair Hussain
Zubair Hussain
SPShe Pengfei
She Pengfei
LYLi Yimin
Li Yimin
LSLiu Shasha
Liu Shasha
LZLi Zehao
Li Zehao
YWYong Wu
Yong Wu
Enterococci are important pathogens of nosocomial infections and are increasingly difficult to treat due to their intrinsic and acquired resistance to a range of antibiotics. Therefore, there is an urgent need to develop novel antibacterial agents, while drug repurposing is a promising approach to address this issue. Our study aimed to determine the antimicrobial efficacy of halicin against enterococci and found that the minimum inhibitory concentrations (MIC) of halicin against different strains of Enterococcus faecalis and Enterococcus faecium ranged from 4 to 8 μg/ml. In addition, the synergistic antibacterial effect between halicin and doxycycline (DOX) against Enterococcus was observed through the checkerboard method, and it was observed that halicin and DOX could significantly synergistically inhibit biofilm formation and eradicate preformed biofilms at sub-MICs. Moreover, the electron microscope results revealed that halicin could also disrupt the bacterial cell membrane at high concentrations. Furthermore, it is also confirmed that the combination of halicin and DOX has no significant cytotoxic effect on erythrocytes and other human-derived cells. In addition, the mouse subcutaneous model and H&E staining showed that the combination of halicin and DOX could effectively reduce the bacterial load and inflammatory infiltration without obvious side effects. In nutshell, these results demonstrate the potential of halicin in combination with DOX as a novel therapy against infections by Enterococcus.

14 December 2022 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
ZLZehao Li
Zehao Li
PSPengfei She
Pengfei She
YLYaqian Liu
Yaqian Liu
LXLanlan Xu
Lanlan Xu
YLYimin Li
Yimin Li
YWYong Wu
Yong Wu
Extensively drug-resistant (XDR) Acinetobacter baumannii poses a severe threat to public health due to its ability to form biofilms and persister cells, which contributes to critical drug resistance and refractory device-associated infections. A novel strategy to alleviate such an emergency is to identify promising compounds that restore the antimicrobial susceptibility of existing antibiotics against refractory infections. Here, we found a significant synergy among three combinations of SPR741, clarithromycin and erythromycin with a potent antimicrobial activity against XDR A. baumannii (SPR741/CLA/E at 8/10/10 μg ml–1 for XDR AB1069 and at 10/16/10 μg ml–1 for XDR AB1208, respectively). Moreover, the triple combination therapy exhibits a significant antipersister and antibiofilm effect against XDR strains. Mechanistic studies demonstrate that SPR741 may promote intracellular accumulation of macrolides by permeabilizing the outer membrane as well as disrupting membrane potential and further enhance the quorum sensing inhibition activity of the macrolides against XDR A. baumannii and its biofilms. In addition, the triple combination of SPR741 with clarithromycin and erythromycin was not easy to induce resistance in A. baumannii and had effective antimicrobial activity with low toxicity in vivo. Collectively, these results reveal the potential of SPR741 in combination with clarithromycin and erythromycin as a clinical therapy for refractory infections caused by XDR A. baumannii.

16 March 2023 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
WYWu Yong
Wu Yong
ZHZubair Hussain
Zubair Hussain
LHLui Hongcai
Lui Hongcai
ZLZhu Ling
Zhu Ling
MNMuhammad Asad Nawaz
Muhammad Asad Nawaz
ANAdnan Falak Naz
Adnan Falak Naz
The article has been withdrawn at the request of the authors of the journal "Current Drug Delivery", Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

15 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MNMuhammad Asad Nawaz
Muhammad Asad Nawaz
ZHZubair Hussain
Zubair Hussain
LSLing Shuying
Ling Shuying
LZLing Zhu
Ling Zhu
ANAdnan Naz
Adnan Naz
YRYu Rian
Yu Rian
Background Oesophageal squamous-cell carcinoma (ESCC) is a leading cause of cancer death in low and middle SDI regions. We characterised the heterogeneity of mortality trajectories across six world regions using contemporary methods. Methods We analysed Global Burden of Disease Study 2021 age-standardised mortality rates (1990-2021) using dynamic-programming changepoint detection, Bayesian state-space forecasting to 2040, Das Gupta demographic decomposition, and stochastic frontier analysis. Results Global ASMR declined from 9.01 to 6.12 per 100,000 (AAPC -1.24% per year, 95% CI -1.49 to -1.01), with a synchronised inflection at 2005. Central Asia showed the steepest decline (AAPC -3.30%), whereas Western Sub-Saharan Africa was the only region with a rising trajectory (AAPC +1.56%). Bayesian projections indicate a further 41% rise in Western Sub-Saharan Africa by 2040. East Asia operated at 40% of the achievable burden minimum. Conclusions ESCC mortality trajectories are diverging globally. Region-specific interventions including tobacco control, hot-beverage cooling, mycotoxin mitigation, and AI-assisted endoscopy are needed to reduce preventable mortality.

27 March 2026
Verified
Preprint
Open access
HZHussain Zubair
Hussain Zubair
This protocol provides a validated workflow for differential gene expression analysis of TCGA RNA-seq data. It covers data retrieval via TCGAbiolinks, normalization decisions, differential expression with DESeq2 and apeglm shrinkage, gene ID conversion, and three pathway analysis approaches: ORA, GSEA, and sample-level scoring with GSVA. Each step includes benchmark values validated against TCGA-LUAD (n=540 tumor, 59 normal). The protocol addresses common pitfalls including inappropriate use of TPM for statistical testing and pre-filtering of gene lists before GSEA.